2026-05-14

Coffee volume spike — 12.3× the 20-day average (12,529 vs 1,018 avg)

Platinum volume spike — 315.5× the 20-day average (15,506 vs 49 avg)

Cocoa volume spike — 12.3× the 20-day average (17,160 vs 1,395 avg)

Soybeans volume spike — 5.3× the 20-day average (251,437 vs 47,515 avg)

Copper volume spike — 19.1× the 20-day average (43,543 vs 2,274 avg)

Corn volume spike — 3.2× the 20-day average (260,137 vs 80,742 avg)

Wheat volume spike — 6.7× the 20-day average (116,857 vs 17,449 avg)

Gold volume spike — 183.5× the 20-day average (99,841 vs 543 avg)

Silver volume spike — 28.6× the 20-day average (52,978 vs 1,854 avg)

Coffee bear 7.2% vs prior close ($296.25 → $274.90)

Cotton volume spike — 2.6× the 20-day average (37,006 vs 14,203 avg)

OSINT: German 10‑yr Yield Slightly Falls, Still Near Multi‑Year Highs

OSINT: Cost of Living Surges 106% Since 2001, Says Fortune

Saudi Arabia (Dhahran): drought conditions detected — potential oil supply impact

OSINT: Guatemala FM says democracy owed to Venezuelan people

Cotton bear 4.0% vs prior close ($86.81 → $83.33)

Silver bear 5.5% vs prior close ($88.89 → $84.01)

Platinum bear 5.4% vs prior close ($2,187.10 → $2,069.70)

NATURAL GAS — speculators net long (+3.0σ vs 52w mean) — contrarian bear signal

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves CAVERJECT IMPULSE (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves IDAMYCIN PFS (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves ZITHROMAX (Pfizer) — new revenue stream

FDA approves LITFULO (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves IDAMYCIN PFS (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves LINCOCIN (Pfizer) — new revenue stream

FDA approves TIKOSYN (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves ZITHROMAX (Pfizer) — new revenue stream

FDA approves TIKOSYN (Pfizer) — new revenue stream

FDA approves CAVERJECT IMPULSE (Pfizer) — new revenue stream

FDA approves IDAMYCIN PFS (Pfizer) — new revenue stream

FDA approves LINCOCIN (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves CAVERJECT IMPULSE (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves LINCOCIN (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves ZITHROMAX (Pfizer) — new revenue stream

FDA approves TIKOSYN (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves OZURDEX (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves FETZIMA (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves ULTANE (AbbVie) — new revenue stream

FDA approves SUCRALFATE (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves CANASA (AbbVie) — new revenue stream

FDA approves SUCRALFATE (AbbVie) — new revenue stream

FDA approves FETZIMA (AbbVie) — new revenue stream

FDA approves CANASA (AbbVie) — new revenue stream

FDA approves FETZIMA (AbbVie) — new revenue stream

FDA approves AVYCAZ (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves ULTANE (AbbVie) — new revenue stream

FDA approves SUCRALFATE (AbbVie) — new revenue stream

FDA approves ULTANE (AbbVie) — new revenue stream

FDA approves OZURDEX (AbbVie) — new revenue stream

FDA approves OZURDEX (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves CANASA (AbbVie) — new revenue stream

FDA approves CRINONE (AbbVie) — new revenue stream

FDA approves CRINONE (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves CRINONE (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves AVYCAZ (AbbVie) — new revenue stream

FDA approves AVYCAZ (AbbVie) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

Debt issued for acquisition financing — deal likely imminent

Ameriprise Financial search volume spiked +83 pts — unusual interest

TSCO job postings down -99% WoW — potential restructuring

Amgen search volume spiked +81 pts — unusual interest

Alphabet Inc. (Class A) search volume spiked +100 pts — unusual interest

NVDA RSI 70.3 — overbought (crossed above 70)

Beat consensus by 20.5% — EPS $1.11 vs $0.9212 estimate

Beat consensus by 8.2% — EPS $1.28 vs $1.1828 estimate

Beat consensus by 38.6% — EPS $0.7 vs $0.505 estimate

Beat consensus by 5.2% — EPS $4.73 vs $4.497 estimate

Missed consensus by 78.7% — EPS $0.43 vs $2.016 estimate

Beat consensus by 9.6% — EPS $1.86 vs $1.6968 estimate

Beat consensus by 110.4% — EPS $3.17 vs $1.5069 estimate

Beat consensus by 15.1% — EPS $1.69 vs $1.4685 estimate

Beat consensus by 7.3% — EPS $1.48 vs $1.3788 estimate

Beat consensus by 10.5% — EPS $1.03 vs $0.9322 estimate

Beat consensus by 5.9% — EPS $1.32 vs $1.2464 estimate

Missed consensus by 6.9% — EPS $0.55 vs $0.5908 estimate

Beat consensus by 6.3% — EPS $3.67 vs $3.4541 estimate

Missed consensus by 10.9% — EPS $3.39 vs $3.8047 estimate

Beat consensus by 597.1% — EPS $0.29 vs $0.0416 estimate

Beat consensus by 57.9% — EPS $23.41 vs $14.8274 estimate

Beat consensus by 76.3% — EPS $6.2 vs $3.5172 estimate

Beat consensus by 27.8% — EPS $1.22 vs $0.9543 estimate

Missed consensus by 5.1% — EPS $0.58 vs $0.6111 estimate

Missed consensus by 8.4% — EPS $0.41 vs $0.4476 estimate

Beat consensus by 32.3% — EPS $0.84 vs $0.6349 estimate

Beat consensus by 38.7% — EPS $0.69 vs $0.4976 estimate

Missed consensus by 14.9% — EPS $0.35 vs $0.4112 estimate

Missed consensus by 10.9% — EPS $0.22 vs $0.2469 estimate

Missed consensus by 7.8% — EPS $0.61 vs $0.6616 estimate

Beat consensus by 14.2% — EPS $0.5 vs $0.4379 estimate

Missed consensus by 9.5% — EPS $0.52 vs $0.5743 estimate

Missed consensus by 6.3% — EPS $0.56 vs $0.5978 estimate

Missed consensus by 10.3% — EPS $3.47 vs $3.8682 estimate

Missed consensus by 463.3% — EPS $-4.2 vs $-0.7456 estimate

Beat consensus by 1142.6% — EPS $12.85 vs $-1.2325 estimate

Beat consensus by 20.7% — EPS $-0.71 vs $-0.8954 estimate

Beat consensus by 7.4% — EPS $1.7 vs $1.5822 estimate

Beat consensus by 19.5% — EPS $1.7 vs $1.423 estimate

Beat consensus by 16.1% — EPS $1.78 vs $1.5331 estimate

Beat consensus by 7.0% — EPS $1.56 vs $1.4585 estimate

Beat consensus by 5.6% — EPS $1.9 vs $1.7993 estimate

Missed consensus by 17.9% — EPS $0.22667 vs $0.2761 estimate

Beat consensus by 7.4% — EPS $1.76 vs $1.639 estimate

Beat consensus by 10.1% — EPS $1.58 vs $1.4355 estimate

Missed consensus by 132.9% — EPS $-0.00293 vs $0.0089 estimate

Missed consensus by 7.3% — EPS $0.25 vs $0.2698 estimate

Beat consensus by 9.7% — EPS $0.01229 vs $0.0112 estimate

Beat consensus by 10.5% — EPS $2.75 vs $2.488 estimate

Beat consensus by 5.4% — EPS $0.84 vs $0.7971 estimate

Beat consensus by 12.7% — EPS $3.34 vs $2.9641 estimate

Beat consensus by 13.1% — EPS $3.3 vs $2.9168 estimate

Beat consensus by 16.6% — EPS $0.05 vs $0.0429 estimate

Beat consensus by 9.9% — EPS $2.27 vs $2.065 estimate

Beat consensus by 7.0% — EPS $3.79 vs $3.5431 estimate

Missed consensus by 8.4% — EPS $2.18 vs $2.3803 estimate

Beat consensus by 9.1% — EPS $3.11 vs $2.851 estimate

Missed consensus by 8.2% — EPS $0.58 vs $0.6316 estimate

Beat consensus by 49.8% — EPS $12.89 vs $8.6063 estimate

Beat consensus by 21.0% — EPS $11.83 vs $9.78 estimate

Beat consensus by 5.7% — EPS $11.44 vs $10.8277 estimate

Beat consensus by 15.3% — EPS $0.68 vs $0.5896 estimate

Beat consensus by 7.4% — EPS $0.68 vs $0.6334 estimate

Beat consensus by 11.8% — EPS $3.6 vs $3.2191 estimate

Beat consensus by 6.1% — EPS $4.38 vs $4.1275 estimate

Beat consensus by 27.7% — EPS $0.82 vs $0.642 estimate

Beat consensus by 14.8% — EPS $1.08 vs $0.9411 estimate

Beat consensus by 9.2% — EPS $0.73351 vs $0.6715 estimate

Beat consensus by 9.4% — EPS $1.34 vs $1.2251 estimate

Beat consensus by 5.8% — EPS $1.4 vs $1.3228 estimate

Missed consensus by 6.1% — EPS $1.23 vs $1.3103 estimate

Beat consensus by 28.7% — EPS $2.68 vs $2.082 estimate

Beat consensus by 26.4% — EPS $2.69 vs $2.1278 estimate

Beat consensus by 51.3% — EPS $3.47 vs $2.2935 estimate

ETH ETF inflow of $134M — institutional buying

ETH ETF inflow of $134M — institutional buying

ETH ETF inflow of $134M — institutional buying

ETH DEX volume/liquidity ratio elevated (0.57x) — strong on-chain trading activity

DXY +0.40% — dollar strength signal